These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 24845012)

  • 21. [Clinical pharmacological aspects of new oral anticoagulants].
    Haschke M
    Ther Umsch; 2012 Nov; 69(11):657-60. PubMed ID: 23117669
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New oral anticoagulant agents - general features and outcomes in subsets of patients.
    Schulman S
    Thromb Haemost; 2014 Apr; 111(4):575-82. PubMed ID: 24452881
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Practical management of new oral anticoagulants after total hip or total knee arthroplasty.
    Klauser W; Dütsch M
    Musculoskelet Surg; 2013 Dec; 97(3):189-97. PubMed ID: 24249360
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy.
    Spyropoulos AC; Douketis JD; Gerotziafas G; Kaatz S; Ortel TL; Schulman S;
    J Thromb Haemost; 2012 Apr; 10(4):692-4. PubMed ID: 22934291
    [No Abstract]   [Full Text] [Related]  

  • 25. Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants.
    Cuker A; Siegal DM; Crowther MA; Garcia DA
    J Am Coll Cardiol; 2014 Sep; 64(11):1128-39. PubMed ID: 25212648
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW; Barillari G
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis.
    Gómez-Outes A; Terleira-Fernández AI; Lecumberri R; Suárez-Gea ML; Vargas-Castrillón E
    Thromb Res; 2014 Oct; 134(4):774-82. PubMed ID: 25037495
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Determination of dabigatran, rivaroxaban and apixaban by ultra-performance liquid chromatography - tandem mass spectrometry (UPLC-MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants.
    Schmitz EM; Boonen K; van den Heuvel DJ; van Dongen JL; Schellings MW; Emmen JM; van der Graaf F; Brunsveld L; van de Kerkhof D
    J Thromb Haemost; 2014 Oct; 12(10):1636-46. PubMed ID: 25142183
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation.
    Harrington AR; Armstrong EP; Nolan PE; Malone DC
    Stroke; 2013 Jun; 44(6):1676-81. PubMed ID: 23549134
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Analysis of the projected utility of dabigatran, rivaroxaban, and apixaban and their future impact on existing Hematology and Cardiology Anticoagulation Clinics at The Johns Hopkins Hospital.
    Carter KL; Streiff MB; Ross PA; Wellman JC; Thomas ML; Kraus PS; Shermock KM
    J Thromb Thrombolysis; 2012 Nov; 34(4):437-45. PubMed ID: 22865256
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potential impact of new oral anticoagulants on the management of atrial fibrillation-related stroke in primary care.
    Harris K; Mant J
    Int J Clin Pract; 2013 Jul; 67(7):647-55. PubMed ID: 23621153
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
    Mantha S; Ansell J
    Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban.
    Gong IY; Kim RB
    Can J Cardiol; 2013 Jul; 29(7 Suppl):S24-33. PubMed ID: 23790595
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Management of direct action oral anticoagulants in the peri-operative period and invasive techniques].
    Llau JV; Ferrandis R; Castillo J; de Andrés J; Gomar C; Gómez-Luque A; Hidalgo F; Torres LM;
    Rev Esp Anestesiol Reanim; 2012; 59(6):321-30. PubMed ID: 22633209
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Primary and secondary prevention with new oral anticoagulant drugs for stroke prevention in atrial fibrillation: indirect comparison analysis.
    Rasmussen LH; Larsen TB; Graungaard T; Skjøth F; Lip GY
    BMJ; 2012 Nov; 345():e7097. PubMed ID: 23129490
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New oral anticoagulants for non-valvular atrial fibrillation--safety issues.
    Barry M
    Ir Med J; 2013 Mar; 106(3):69. PubMed ID: 23951972
    [No Abstract]   [Full Text] [Related]  

  • 37. The new oral anticoagulants in clinical practice.
    Gonsalves WI; Pruthi RK; Patnaik MM
    Mayo Clin Proc; 2013 May; 88(5):495-511. PubMed ID: 23639500
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [New clinical perspectives in the management of oral direct anticoagulant agents].
    Marco P; Zamorano JL; Chana F; Llau JV
    Med Clin (Barc); 2014 Feb; 142(4):171-8. PubMed ID: 23866969
    [No Abstract]   [Full Text] [Related]  

  • 39. Acute management of bleeding in patients on novel oral anticoagulants.
    Siegal DM; Crowther MA
    Eur Heart J; 2013 Feb; 34(7):489-498b. PubMed ID: 23220847
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug and dietary interactions of the new and emerging oral anticoagulants.
    Walenga JM; Adiguzel C
    Int J Clin Pract; 2010 Jun; 64(7):956-67. PubMed ID: 20584229
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.